Emerald Holding (EEX) receives buyout offers, but with no deal yet and overvalued shares, analysts suggest selling. See here ...
Zacks Investment Research on MSN
Is Target stock a buy or sell at its current valuation?
Target Corporation TGT is currently trading at a forward 12-month price-to-earnings (P/E) multiple of 12.84X, which positions it at a discount compared with the Zacks Retail - Discount Stores industry ...
While the NCLT has approved Vedanta's planned demerger, approvals for the Vedanta Power demerger are still pending, with the ...
Cantor Fitzgerald has slashed its price target for Michael Saylor’s MicroStrategy, that is one of the most popular Bitcoin ...
Overall, despite the softening of near-term growth expectations for Blinkit, Eternal remains JM Financial's preferred pick as ...
With the Vodafone turnaround strategy progressing, strong cash flow forecasts could be the key share price driver for the ...
Jefferies and Morgan Stanley raised Apple price targets, citing strong iPhone sales, China growth and pricing power despite ...
The weakening of the INR has no effect on Indraprastha Gas Ltd (IGL) since lower RLNG prices counteract currency pressure.
Palantir Technologies received a vote of confidence from Wall Street ahead of its third-quarter earnings release as Wedbush Securities analyst Daniel Ives boosted his price target on the AI-focused ...
SAIL: Nuvama said there an adverse supply outlook for flat steel, weak margin visibility and an impending capex-led rise in ...
24/7 Wall St. on MSN
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs
Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying recently.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback